EpiBiologics

EpiBiologics is a biotechnology company headquartered in San Mateo, California. Founded in 2022, the company employs 38 people and is backed by leading healthcare investors. EpiBiologics is developing a next-generation protein degradation platform called EpiTAC. This proprietary, modular antibody-based system allows for the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. The company aims to leverage this platform to develop first-in-class and best-in-class targeted therapies for multiple therapeutic areas. EpiBiologics' technology is based on the pioneering work of academic founder Dr. Jim Wells of the University of California San Francisco (UCSF). For more information about EpiBiologics and its groundbreaking work, please visit epibiologics.com and follow the company on LinkedIn.